SCHEMBL2323530

SCHEMBL2323530

N#Cc1ccc(NCC(=O)N2CCc3nc4ccccc4c(C(=O)N4CCOCC4)c3C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ PDE5A O76074 7/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ PDE6D O43924 1/20 0.39
▸ PDE6A P16499 1/20 0.39
▸ PDE6G P18545 1/20 0.39
▸ PDE6B P35913 1/20 0.39
▸ PDE6C P51160 1/20 0.39
▸ PDE6H Q13956 1/20 0.39
▸ PIK3CD O00329 1/20 0.38
▸ PIK3R2 O00459 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2449912 0.92 ALDH1A1 (0.45) MAPTKDM4EALDH1A1HTTPIK3CD
SCHEMBL2319203 0.91 PIK3CD (0.43) MAPTALDH1A1PDE5ACYP3A4CYP2D6
SCHEMBL2321559 0.90 MAPT (0.44) MAPTKDM4EALDH1A1HTTPDE5A
SCHEMBL2450519 0.82 SMN1; SMN2 (0.43) MAPTKDM4EALDH1A1HTTPDE5A
SCHEMBL2317218 0.81 MAPT (0.45) MAPTKDM4EALDH1A1HTTMEN1
SCHEMBL2322437 0.78 FKBP1A (0.55) ALDH1A1PIK3CDPIK3R2PIK3CAPIK3CB
SCHEMBL26454872 0.76 MAPT (0.61) MAPTKDM4EALDH1A1HTTMEN1
SCHEMBL2321096 0.73 FKBP1A (0.43) KDM4EALDH1A1PIK3CDPIK3R2PIK3CA
SCHEMBL2320640 0.73 ALDH1A1 (0.60) MAPTKDM4EALDH1A1HTTPIK3CD
SCHEMBL2451622 0.73 FKBP1A (0.45) MAPTALDH1A1PIK3CDPIK3R2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230471-A1 BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-09-22 — — US disclosed
US-20110230471-A1 BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-09-22 — — US disclosed
EP-2352733-A1 BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN Merck Patent GmbH (DE) 2011-08-10 — — EP disclosed
WO-2010060532-A1 BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN MERCK PATENT GMBH (DE) 2010-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230471-A1 BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN ENPP2, TPX2, TPD52L2 MAPT 2887/4885KDM4E 1953/4885ALDH1A1 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback